Le Lézard
Classified in: Environment, Science and technology
Subject: RCY

Suzano removes 11.75 million tons of CO2e from the atmosphere in 2019


SÃO PAULO, June 5, 2020 /PRNewswire/ -- Suzano, the global reference in the production of bioproducts from planted eucalyptus, reports its first Greenhouse Gas Inventory with consolidated data after the merger that originated the new company. The result of emissions and removal of greenhouse gases generated a climate positive balance of 11.75 million tons of CO2equivalent in 2019. In other words, the company removed almost 12 million tons of CO2e in 2019 from the atmosphere.

Suzano's Inventory shows that the company captured the equivalent of 15.48 million tons of CO2e from its forest base consisting of planted and preservation areas. This number is four times higher than the emissions recorded in the same period, which amounted to 3.72 million tons of CO2. These removal and emission numbers may vary each year depending on the volume of eucalyptus planted and harvested, the growth of native forests, mill production volume and the volume of product delivered to our clients.

Studies show that approximately 12 million tons of CO2e, from the total 15.48 million tons of CO2e, were removed from the atmosphere as a result of the company's extensive planted area. This number reflects both the quantity of standing eucalyptus forests and the volume of wood that was harvested, which was lower in 2019. Native forests, on the other hand, helped remove 3.34 million tons of CO2e. This is a positive number since native forests are evolving towards more advanced stages. Suzano has a forestry base consisting of approximately 1.3 million hectares of planted areas and 900,000 hectares of preserved areas.

"Last year we captured much more carbon from the atmosphere than we emitted, and we will continue this trend as we have announced publicly in our long-term targets," said Cristiano Resende, Manager ? Sustainability at Suzano.

Suzano's targets include removing 40 million tons of CO2e from the atmosphere by 2030. The company also aims to reduce specific emissions from its operations by 15% over the next ten years. With this, it aims to be even more climate positive and help mitigate the factors that cause climate changes. 

Calculating the impacts caused using the inventory helps to identify opportunities and define future strategies. The calculations in the report were made jointly with consulting firm Plantar Carbon and were audited by Bureau Veritas.

PLANIN ? Suzano's PR Agency 
Angélica Consiglio, Beatriz Imenes ? www.planin.com 
E-mail: [email protected] - Phone: +55 (11) 2138-8940 

SOURCE Suzano


These press releases may also interest you

at 07:15
Draganfly Inc. ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions and systems developer is pleased to announce a strategic collaboration with ParaZero Technologies Ltd., a pioneer in drone safety systems aimed at...

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:07
MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the Document Solutions v7.1 release. This release introduces features and enhancements to MESCIUS's server-side document APIs, JavaScript...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...



News published on and distributed by: